Dipeptidyl peptidase IV (DPP-IV) inhibition prevents fibrosis in adipose tissue of obese mice

• Autor(a) principal: Marques, Ana Patrícia
• Data de Publicação: 2018
• Outros Autores: Cunha-Santos, Janete, Leal, Helena, Sousa-Ferreira, Lígia, Pereira de Almeida, Luís, Cavadas, Cláudia, Rosmaninho-Salgado, Joana
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
• Texto Completo: http://hdl.handle.net/10316/88152; https://doi.org/10.1016/j.bbagen.2017.11.012
• topic: Dipeptidyl peptidase IV inhibitor; Extracellular matrix; Fibrosis; Neuropeptide Y; Obesity; Vildagliptin

During the development of obesity the expansion of white adipose tissue (WAT) leads to a dysregulation and an excessive remodeling of extracellular matrix (ECM), leading to fibrosis formation. These ECM changes have high impact on WAT physiology and may change obesity progression. Blocking WAT fibrosis may have beneficial effects on the efficacy of diet regimen or therapeutical approaches in obesity. Since dipeptidyl peptidase IV (DPP-IV) inhibitors prevent fibrosis in tissues, such as heart, liver and kidney, the objective of this study was to assess whether vildagliptin, a DPP-IV inhibitor, prevents fibrosis in WAT in a mouse model of obesity, and to investigate the mechanisms underlying this effect.